ALLK - Allakos Inc

-

$undefined

N/A

(N/A)

Allakos Inc NASDAQ:ALLK Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.

Location: 975 Island Dr Ste 201, California, 94065-5173, US | Website: www.allakos.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-22.08M

Cash

123.1M

Avg Qtr Burn

-25.8M

Short % of Float

3.31%

Insider Ownership

2.33%

Institutional Own.

88.10%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AK006 (IV) Details
Chronic spontaneous urticaria

Phase 1

Data readout

AK006 (SC) Details
Chronic spontaneous urticaria

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Lirentelimab (AK002) (Siglec-8) Details
Eosinophilic Duodentitis , Eosinophilic Gastritis

Failed

Discontinued